Ipsen's billion-dollar drug Somatoline is maintaining strong sales despite facing generic competition since 2021. The drug is extremely difficult to manufacture, which has prevented generic players from ramping up production. This "manufacturing moat" serves as a powerful, often overlooked, defense against revenue erosion after a patent cliff.

While many focus on identifying a few high-"quality" neoantigen targets, Newscom argues that quantity is equally crucial. By presenting a broad set of over 200 targets in its vaccine, the company aims to significantly reduce the chance of tumor escape, as cancer cannot easily downregulate all targets at once.

Machine learning's application in multi-specific antibody design is hampered by a lack of public data. Companies must invest heavily in generating their own large-scale, proprietary datasets to train effective models, creating a significant barrier to entry and a competitive advantage.

Instead of optimizing ADC linker-payload technology like many competitors, Ona Therapeutics licenses best-in-class components. Their unique edge comes from identifying novel tumor antigens by analyzing sequential patient biopsies from Spanish hospitals, a proprietary data source that provides a durable competitive advantage.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Infinitopes' platform uses immunopeptidomics to directly measure peptides on a tumor's surface. This contrasts with competitors like Moderna and BioNTech, who rely on computational predictions from DNA sequencing. This "measure, don't predict" approach aims for more reliable identification of potent immune targets.

While Moderna's Phase 3 success is a scientific breakthrough, its real-world application is uncertain. The personalized nature creates a significant manufacturing burden and high cost, raising questions about whether payers will reimburse an expensive therapy used to delay, not cure, cancer in a broad adjuvant setting.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.